Literature DB >> 11886658

Formation of vascularized meniscal tissue by combining gene therapy with tissue engineering.

Chisa Hidaka1, Clemente Ibarra, Jo A Hannafin, Peter A Torzilli, Mannix Quitoriano, Shih-Shi Jen, Russell F Warren, Ronald G Crystal.   

Abstract

Ingrowth of host blood vessels into engineered tissues has potential benefits for successful transplantation of engineered tissues as well as healing of surrounding host tissues. In particular, the use of a vascularized bioengineered tissue could be beneficial for treating injuries to the meniscus, a structure in the knee where the lack of a vascular supply is associated with an inadequate healing response. In this study, gene transfer using an adenovirus vector encoding the hepatocyte growth factor gene (AdHGF) was used to induce blood vessel formation in tissue-engineered meniscus. Bovine meniscal cells were treated with AdHGF, a vector encoding a marker gene E. coli beta-galactosidase (Adbetagal), or no virus. Cells were seeded onto poly-glycolic acid felt scaffolds and then transplanted into the subcutaneous pouch of athymic nude mice for 8 weeks. Expression of the marker gene and HGF was detectable for several weeks after gene transfer. Ink injection studies showed that AdHGF-treated meniscal cells formed tissue which contained fourfold more blood vessels at 2 weeks (p < 0.02) and 2.5-fold more blood vessels at 8 weeks (p < 0.001) posttransplantation than controls. This study demonstrates the feasibility of using adenovirus-mediated gene transfer to engineer a blood supply in the bioengineered meniscal tissue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11886658     DOI: 10.1089/107632702753503090

Source DB:  PubMed          Journal:  Tissue Eng        ISSN: 1076-3279


  16 in total

1.  Meniscus Repair and Regeneration: A Systematic Review from a Basic and Translational Science Perspective.

Authors:  John Twomey-Kozak; Chathuraka T Jayasuriya
Journal:  Clin Sports Med       Date:  2020-01       Impact factor: 2.182

Review 2.  [Gene therapy in orthopaedic surgery].

Authors:  H Madry; D Kohn; M Cucchiarini
Journal:  Orthopade       Date:  2006-11       Impact factor: 1.087

Review 3.  Engineering orthopedic tissue interfaces.

Authors:  Peter J Yang; Johnna S Temenoff
Journal:  Tissue Eng Part B Rev       Date:  2009-06       Impact factor: 6.389

4.  Updates in biological therapies for knee injuries: menisci.

Authors:  Camila Cohen Kaleka; Pedro Debieux; Diego da Costa Astur; Gustavo Gonçalves Arliani; Moisés Cohen
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

Review 5.  Use of tissue engineering strategies to repair joint tissues in osteoarthritis: viral gene transfer approaches.

Authors:  Magali Cucchiarini; Henning Madry
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

6.  Meniscal Tissue Engineering Using Aligned Collagen Fibrous Scaffolds: Comparison of Different Human Cell Sources.

Authors:  Jihye Baek; Sujata Sovani; Wonchul Choi; Sungho Jin; Shawn P Grogan; Darryl D D'Lima
Journal:  Tissue Eng Part A       Date:  2017-06-13       Impact factor: 3.845

Review 7.  Manipulating the microvasculature and its microenvironment.

Authors:  Laxminarayanan Krishnan; Carlos C Chang; Sara S Nunes; Stuart K Williams; Jeffrey A Weiss; James B Hoying
Journal:  Crit Rev Biomed Eng       Date:  2013

Review 8.  Advances in combining gene therapy with cell and tissue engineering-based approaches to enhance healing of the meniscus.

Authors:  M Cucchiarini; A L McNulty; R L Mauck; L A Setton; F Guilak; H Madry
Journal:  Osteoarthritis Cartilage       Date:  2016-04-05       Impact factor: 6.576

9.  Treating human meniscal fibrochondrocytes with hIGF-1 gene by liposome.

Authors:  Hai-ning Zhang; Ping Leng; Ying-zhen Wang; Jie Zhang
Journal:  Clin Orthop Relat Res       Date:  2009-05-08       Impact factor: 4.176

10.  Enhanced meniscal repair by overexpression of hIGF-1 in a full-thickness model.

Authors:  Haining Zhang; Ping Leng; Jie Zhang
Journal:  Clin Orthop Relat Res       Date:  2009-06-13       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.